How to buy Sage Therapeutics stock | 73.47

Sage Therapeutics, Inc is a biotechnology business based in the US. Sage Therapeutics shares (SAGE) are listed on the NASDAQ and all prices are listed in US Dollars. Sage Therapeutics employs 675 staff and has a trailing 12-month revenue of around USD$8.9 million.

How to buy shares in Sage Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Sage Therapeutics. Find the stock by name or ticker symbol: SAGE. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sage Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$73.47, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Sage Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Sage Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Sage Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Sage Therapeutics's share price has had significant positive movement.

Its last market close was USD$73.47, which is 5.36% up on its pre-crash value of USD$69.53 and 193.76% up on the lowest point reached during the March crash when the shares fell as low as USD$25.01.

If you had bought USD$1,000 worth of Sage Therapeutics shares at the start of February 2020, those shares would have been worth USD$388.07 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,090.29.

Sage Therapeutics share price

Use our graph to track the performance of SAGE stocks over time.

Sage Therapeutics shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$73.47
52-week range	USD$25.01 - USD$155.33
50-day moving average	USD$59.64
200-day moving average	USD$45.7324
Wall St. target price	USD$79.05
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-12.679

Buy Sage Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Sage Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Sage Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sage Therapeutics price performance over time

Historical closes compared with the close of $73.47 from 2020-11-16

1 week (2020-11-15)	N/A
1 month (2020-10-26)	7.26%
3 months (2020-08-22)	N/A
6 months (2020-05-22)	88.67%

1 year (2019-11-22)	-50.69%
2 years (2018-11-22)	N/A
3 years (2017-11-22)	-23.02%
5 years (2015-11-22)	N/A

Is Sage Therapeutics under- or over-valued?

Valuing Sage Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sage Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sage Therapeutics's PEG ratio

Sage Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.74. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sage Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Sage Therapeutics financials

Revenue TTM	USD$8.9 million
Gross profit TTM	USD$-362,347,000
Return on assets TTM	-35.24%
Return on equity TTM	-62.97%
Profit margin	0%
Book value	$14.247
Market capitalisation	USD$3.6 billion

TTM: trailing 12 months

Shorting Sage Therapeutics shares

There are currently 6.2 million Sage Therapeutics shares held short by investors – that's known as Sage Therapeutics's "short interest". This figure is 14.5% down from 7.3 million last month.

There are a few different ways that this level of interest in shorting Sage Therapeutics shares can be evaluated.

Sage Therapeutics's "short interest ratio" (SIR)

Sage Therapeutics's "short interest ratio" (SIR) is the quantity of Sage Therapeutics shares currently shorted divided by the average quantity of Sage Therapeutics shares traded daily (recently around 721251.80023229). Sage Therapeutics's SIR currently stands at 8.61. In other words for every 100,000 Sage Therapeutics shares traded daily on the market, roughly 8610 shares are currently held short.

However Sage Therapeutics's short interest can also be evaluated against the total number of Sage Therapeutics shares, or, against the total number of tradable Sage Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sage Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Sage Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.1651% of the tradable shares (for every 100,000 tradable Sage Therapeutics shares, roughly 165 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Sage Therapeutics.

Find out more about how you can short Sage Therapeutics stock.

Sage Therapeutics share dividends

We're not expecting Sage Therapeutics to pay a dividend over the next 12 months.

Sage Therapeutics share price volatility

Over the last 12 months, Sage Therapeutics's shares have ranged in value from as little as $25.01 up to $155.33. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sage Therapeutics's is 2.455. This would suggest that Sage Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Sage Therapeutics overview

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Sage Therapeutics is owned by insiders or institutions?

  Currently 1.831% of Sage Therapeutics shares are held by insiders and 109.71% by institutions.

• How many people work for Sage Therapeutics?

  Latest data suggests 675 work at Sage Therapeutics.

• When does the fiscal year end for Sage Therapeutics?

  Sage Therapeutics's fiscal year ends in December.

• Where is Sage Therapeutics based?

  Sage Therapeutics's address is: 215 First Street, Cambridge, MA, United States, 02142

• What is Sage Therapeutics's ISIN number?

  Sage Therapeutics's international securities identification number is: US78667J1088

• What is Sage Therapeutics's CUSIP number?

  Sage Therapeutics's Committee on Uniform Securities Identification Procedures number is: 78667J108